Nektar Therapeutics (NASDAQ:NKTR) Just Reported And …
3 days ago · NKTR. Nektar Therapeutics (NASDAQ:NKTR) investors will be delighted, with the company turning in some strong numbers with its latest results. Revenues of US$24m beat estimates by a substantial 32% ...
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: …
6 days ago · NKTR. Revenue: $24.1 million for Q3 2024. Full Year Revenue Guidance: Expected between $90-95 million. Cash and Investments: $249 million at the end of Q3 2024. Net Loss: $37 million or $0.18 per ...
Nektar Therapeutics Third Quarter 2024 Earnings: Beats …
4 days ago · Nektar Therapeutics (NASDAQ:NKTR) Third Quarter 2024 Results. Revenue: US$24.1m (flat on 3Q 2023). Net loss: US$37.1m (loss narrowed by 19% from 3Q 2023). US$0.18 loss per share (improved from US ...
Nektar presents late-breaking results from Phase 2 Study of NKTR …
Nov 7, 2024 · Nektar Therapeutics GAAP EPS of -$0.18 beats by $0.03, revenue of $24.12M beats by $5.84M Seeking Alpha 2d Nektar releases promising phase 2 results for NKTR-255 in lymphopenia
Press Releases - Nektar Therapeutics
Oct 17, 2024 · Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Oct 17, 2024. Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024. Sep 25, 2024.
Nektar Therapeutics to Participate in Upcoming Investor …
SAN FRANCISCO, Nov. 6, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, November 13, 2024 at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific Time – webcast link here.
Nektar Therapeutics Reports Third Quarter 2024 Financial Results
Sep 30, 2024 · SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are ...
Nektar Therapeutics Announces Strategic Reprioritization and …
SAN FRANCISCO, April 17, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced a strategic reprioritization and cost restructuring plan that includes a new pipeline focus on...
Nektar Therapeutics Announces Initiation of Phase 2b Clinical …
SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the...
Nektar to sell its Huntsville, Alabama facility to Ampersand Capital ...
TipRanks. Nov. 4, 2024, 07:35 AM. Nektar (NKTR) Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and reagent supply ...
- Some results have been removed